Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relief ACP Oral Care Gel is a topical desensitizing and remineralizing treatment developed and marketed by Philips Oral Healthcare. It is formulated with 5% potassium nitrate, 0.22% sodium fluoride, and amorphous calcium phosphate (ACP), a proprietary technology licensed from the ADA Foundation. The gel employs a dual-action mechanism to address dentin hypersensitivity: potassium nitrate provides rapid chemical desensitization by interfering with nerve transmission, while ACP and fluoride work synergistically to remineralize tooth enamel and occlude dentin tubules by precipitating hydroxyapatite and fluorapatite. It is primarily indicated for the relief of sensitivity caused by gum recession, root exposure, post-root planing, and tooth whitening procedures. Additionally, it has been evaluated in clinical trials as an adjunct for masking dental fluorosis and staining.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relief ACP Oral Care Gel.